Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Phase 4

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2006-09-12

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 404

Registration Number: NCT00375284

Locations: 🇺🇸
248.616.035 Boehringer Ingelheim Investigational Site, Mesa, Arizona, United States
🇺🇸
248.616.049 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States
🇺🇸
248.616.066 Boehringer Ingelheim Investigational Site, Savannah, Georgia, United States

and more 49 locations

An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2006-08-17

Last Posted Date: 2013-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 115

Registration Number: NCT00365560

Locations: 🇳🇱
lokatie het Spittaal, Zutphen, Netherlands
🇳🇱
Polikliniek longziekten, Hengelo, Netherlands
🇩🇪
Boehringer Ingelheim Investigational Site, Wiesloch, Germany

and more 2 locations

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-08-02

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 349

Registration Number: NCT00359788

Locations: 🇺🇸
205.325.935 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸
205.325.917 Boehringer Ingelheim Investigational Site, Buffalo, New York, United States
🇺🇸
205.325.924 Boehringer Ingelheim Investigational Site, East Orange, New Jersey, United States

and more 28 locations

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Phase 4

Completed

Conditions: Restless Legs Syndrome
Depression

First Posted Date: 2006-07-25

Last Posted Date: 2012-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 404

Registration Number: NCT00356096

Locations: 🇫🇮
248.604.35801 Boehringer Ingelheim Investigational Site, Espoo, Finland
🇰🇷
248.604.82003 Boehringer Ingelheim Investigational Site, Incheon, Korea, Republic of
🇮🇹
248.604.3909 IRCCS Fondazione "Salvatore Maugeri", Telese Terme (be), Italy

and more 51 locations

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2006-07-10

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 388

Registration Number: NCT00350207

Locations: 🇧🇪
205.342.32003 Boehringer Ingelheim Investigational Site, Herentals, Belgium
🇦🇹
205.342.43005 Boehringer Ingelheim Investigational Site, Wien, Austria
🇧🇪
205.342.32002 Boehringer Ingelheim Investigational Site, Brussel, Belgium

and more 106 locations

A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS

Phase 4

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2006-07-07

Last Posted Date: 2012-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 369

Registration Number: NCT00349531

Locations: 🇬🇧
248.615.44009 Boehringer Ingelheim Investigational Site, Reading, United Kingdom
🇪🇸
248.615.3404 Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸
248.615.3408 Hospital Nuestra Señora de Sonsoles, Avila, Spain

and more 46 locations

Profile of Depressive Symptoms in Parkinsons Disease

Completed

Conditions: Depression
Parkinson Disease

First Posted Date: 2006-07-06

Last Posted Date: 2023-12-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1018

Registration Number: NCT00349310

Locations: 🇫🇷
Hopital Purpan, Toulouse cedex, France
🇬🇧
Boehringer Ingelheim Investigational Site, Newark, United Kingdom
🇩🇪
Parkinson Klinik Wolfach, Wolfach, Germany

and more 15 locations

Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

Phase 3

Completed

Conditions: Sleep Initiation and Maintenance Disorders

First Posted Date: 2006-07-04

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 253

Registration Number: NCT00347295

Locations: 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Shanghai Mental Health Center, Shanghai, China

and more 5 locations

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Phase 2

Completed

Conditions: Bladder, Neurogenic

Interventions: Drug: tamsulosin hydrochloride

First Posted Date: 2006-06-21

Last Posted Date: 2016-02-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 143

Registration Number: NCT00340704

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BIRT 2584 XX
Drug: Placebo

First Posted Date: 2006-06-05

Last Posted Date: 2014-06-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 360

Registration Number: NCT00333411

Locations: 🇫🇷
Hôpital Dupuytren, Limoges cedex 1, France
🇩🇪
Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
🇩🇪
Johannes Gutenberg-Universität Mainz, Mainz, Germany

and more 36 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy